




UNITED STATES PATENT AND TRADEMARK OFFICE


 Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/018,729	FIRST NAMED APPLICANT Raphael Darteil	ATTY. DOCKET NO. ST99021 US PCT
---	--	------------------------------------

 005487
 AVENTIS PHARMACEUTICALS, INC.
 PATENTS DEPARTMENT
 ROUTE 202-206, P.O. BOX 6800
 BRIDGEWATER, NJ 08807-0800


INTERNATIONAL APPLICATION NO. PCT/FR00/01744	
I.A. FILING DATE 06/22/2000	PRIORITY DATE 06/22/1999

 CONFIRMATION NO. 5011
 371 FORMALITIES LETTER


OC00000008372320

Date Mailed: 07/01/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of **ONE MONTH** from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Additionally the following defects have been observed:

The following items **MUST** be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

■ APPLICANT MUST PROVIDE:

- A statement that the contents of the paper or compact disc and the computer readable form are the

same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- Additional claim fees of \$36 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$36 for a Large Entity:

- Total additional claim fee(s) for this application is \$36
 - \$36 for 17 total claims over 20.

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/018,729	PCT/FR00/01744	ST99021 US PCT



PATENT
ST99021 US PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): DARTEIL ET AL. EXAMINER : UNASSIGNED
SERIAL NO. : 10/018,729 ART UNIT : UNASSIGNED
FILED : DECEMBER 18, 2001
FOR : SYSTEM OR REGULATION OF EXPRESSION USING PPAR
NUCLEAR RECEPTOR

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as FIRST CLASS MAIL in an envelope addressed to the COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on August 5, 2002.

(Signature and Date)

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER OF PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

In response to the Examiner's communication of July 1, 2002, enclosed herein, please find the following:

1. Paper copy of sequence listing
2. Diskette containing computer readable form of sequence listing;
3. A petition for a one (1) month extension to respond;
4. Statement under 37 CFR 1.821(c); and
5. Copy of the Examiner's communication.

Fees

No additional fees are believed to be necessitated by the foregoing Response. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 18-1982 for any underpayment, or credit any overages.

CONCLUSION

Early and favorable action on the merits is courteously solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'William C. Coppola', written over a horizontal line.

WILLIAM C. COPPOLA

Registration No. 41686

03/21/2002 LLAHDGRA 00000022 181982 10018729

02 FC:966 36.00 CH

AVENTIS PHARMACEUTICALS PRODUCTS, INC.
Route 202-206; Mail Stop: EMC-G1
P.O. Box 6800
Bridgewater, NJ 08807
August 5, 2002